已发表论文

康多机器人与达芬奇机器人辅助子宫内膜癌手术的回顾性对比研究

 

Authors Liu T, Ma L, Wang Y, Wang B, Xu Y, Gao Y, Yu G, Gao J , Chen J 

Received 18 March 2025

Accepted for publication 18 June 2025

Published 7 July 2025 Volume 2025:18 Pages 3891—3900

DOI https://doi.org/10.2147/JMDH.S525579

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Pavani Rangachari

Tianbo Liu,* Li Ma,* Yan Wang, Bo Wang, Yue Xu, Ying Gao, Ge Yu, Jialiang Gao, Jie Chen

Department of Gynecological Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Jie Chen, Email cj2365255@126.com

Background: With the advancement of medical technology, robotic-assisted surgery has emerged as a promising approach for the management of endometrial cancer (EC). This retrospective comparative study aimed to evaluate the efficacy, safety, and functional outcomes of two robotic systems—Kangduo (KD-RAS) and Da Vinci (DV-RAS)—in the treatment of EC.
Methods: This study included patients with stage T1 EC who underwent robotic-assisted surgery using either the Kangduo or Da Vinci system at Harbin Medical University Cancer Hospital. A comprehensive statistical analysis was conducted on their perioperative clinical data, encompassing preoperative, intraoperative, and postoperative parameters.
Results: A total of 211 patients were enrolled in this study, including 125 in the KD-RAS group and 86 in the DV-RAS group. The surgical success rate was 100% in both groups, with no significant differences observed in preoperative baseline characteristics (P > 0.05). There were also no significant differences between the two groups in terms of blood loss, transfusion requirements, or Clavien-Dindo grade I/II complications (P > 0.05). However, the KD-RAS group exhibited longer operation time, console time, time to first flatus, and length of hospital stay compared to the DV-RAS group (P < 0.05). Notably, both total hospitalization costs and surgical expenses were significantly lower in the KD-RAS group than in the DV-RAS group (P < 0.05).
Conclusion: The Kangduo robotic system demonstrates comparable efficacy and equivalent safety profiles to the Da Vinci system, supporting its non-inferiority in clinical performance for the treatment of early-stage endometrial cancer.

Keywords: endometrial cancer, Kangduo robotic system, Da Vinci robotic system, efficacy, safety